Literature DB >> 25150172

Relationship of the number of removed lymph nodes to bladder cancer and competing mortality after radical cystectomy.

Michael Froehner1, Vladimir Novotny2, Ulrike Heberling2, Lydia Rutsch2, Rainer J Litz3, Matthias Hübler4, Rainer Koch5, Gustavo B Baretton6, Manfred P Wirth2.   

Abstract

UNLABELLED: The extent of lymph node dissection in radical cystectomy is a subject of controversy. A more extended dissection has been reported to be associated with superior survival. We analyzed the relationship between the lymph node count and different causes of death in a sample of 735 patients who underwent radical cystectomy for recurrent or muscle-invasive urothelial or undifferentiated carcinoma of the bladder. The median follow-up was 7.8 yr. The median lymph node count was 17, and the median age was 67 yr. Although there was a clear association between lymph node count and overall survival (≥21 vs. <10 lymph nodes: 10-yr rates: 59% vs. 32%, respectively; hazard ratio: 0.63; 95% confidence interval, 0.46-0.87; log-rank test: p=0.0056), there was no detectable relationship between bladder cancer mortality and lymph node count (narrowly congruent cumulative mortality curves, Pepe-Mori test, p values ranging between 0.40 and 0.93). The differences were virtually entirely attributable to differences in competing mortality. These observations indicate that serious bias may occur when the lymph node count is used to stratify patients undergoing radical cystectomy. The results of the ongoing randomized trials should be awaited to reliably answer the question of the degree to which more extensive dissection may improve outcome. PATIENT
SUMMARY: Survival differences in patients stratified by lymph node count may be attributed to competing mortality. The results of ongoing randomized trials should be awaited to answer the question of the degree to which more extensive lymph node dissection may improve outcome.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant; Bladder; Chemotherapy; Cystectomy; Lymph nodes; Proportional hazards model; Urologic neoplasms

Mesh:

Year:  2014        PMID: 25150172     DOI: 10.1016/j.eururo.2014.07.046

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

1.  Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.

Authors:  Stephen B Williams; Yong Shan; Usama Jazzar; Hemalkumar B Mehta; Jacques G Baillargeon; Jinhai Huo; Anthony J Senagore; Eduardo Orihuela; Douglas S Tyler; Todd A Swanson; Ashish M Kamat
Journal:  JAMA Surg       Date:  2018-10-01       Impact factor: 14.766

2.  Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.

Authors:  Stephen B Williams; Jinhai Huo; Christopher D Kosarek; Karim Chamie; Selwyn O Rogers; Michele A Williams; Sharon H Giordano; Simon P Kim; Ashish M Kamat
Journal:  Cancer Causes Control       Date:  2017-05-05       Impact factor: 2.506

Review 3.  Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Curr Urol Rep       Date:  2018-10-24       Impact factor: 3.092

4.  Lee mortality index as comorbidity measure in patients undergoing radical cystectomy.

Authors:  Michael Froehner; Rainer Koch; Vladimir Novotny; Ulrike Heberling; Stefan Propping; Rainer J Litz; Matthias Hübler; Gustavo B Baretton; Oliver W Hakenberg; Manfred P Wirth
Journal:  Springerplus       Date:  2015-02-03

5.  EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study.

Authors:  Christa A M van der Fels; Stefano Rosati; Igle J de Jong
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

6.  Extent of lymphadenectomy in patients with bladder cancer undergoing radical cystectomy - a multi-institutional analysis.

Authors:  Sebastian Piotrowicz; Sławomir Poletajew; Stefan W Czarniecki; Filip Kowalski; Grzegorz Nowak; Maciej Oszczudłowski; Marta Sochaj; Jakub Dobruch; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2016-10-19

7.  Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition via the Hippo signaling pathway in human bladder cancer.

Authors:  Lyu Zhaojie; Liu Yuchen; Chen Miao; Chen Yacun; Wu Shayi; He Anbang; Liao Xinhui; Zhang Meng; Wu Peipei; Mei Hongbing; Wang Feng; Cai Zhiming; Guan Xinyuan
Journal:  Ther Adv Med Oncol       Date:  2019-04-29       Impact factor: 8.168

Review 8.  The evolving role of lymphadenectomy for bladder cancer: why, when, and how.

Authors:  Vignesh T Packiam; Matvey Tsivian; Stephen A Boorjian
Journal:  Transl Androl Urol       Date:  2020-12

9.  A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis.

Authors:  Fei Li; Xuwei Hong; Lina Hou; Fengsheng Lin; Pengliang Chen; Shiyu Pang; Yuejun Du; He Huang; Wanlong Tan
Journal:  Oncotarget       Date:  2016-09-20

10.  Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris.

Authors:  André Oszwald; Gabriel Wasinger; Laura Larnaudie; Justine Varinot; Philippe Sebe; Olivier Cussenot; Eva Compérat
Journal:  World J Urol       Date:  2021-03-20       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.